499 related articles for article (PubMed ID: 33960680)
41. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
42. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
43. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of ubiquitin-specific protease 2a (USP2a) and nuclear factor erythroid 2-related factor 2 (Nrf2) in human gliomas.
Boustani MR; Khoshnood RJ; Nikpasand F; Taleshi Z; Ahmadi K; Yahaghi E; Goudarzi PK
J Neurol Sci; 2016 Apr; 363():249-52. PubMed ID: 27000259
[TBL] [Abstract][Full Text] [Related]
45. Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas.
Yang P; Wang K; Zhang C; Wang Z; Liu Q; Wang J; Jiang T; Shan X
Cancer Immunol Immunother; 2021 Sep; 70(9):2589-2600. PubMed ID: 33576871
[TBL] [Abstract][Full Text] [Related]
46. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
47. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract][Full Text] [Related]
48. Expression and prognostic value of long non-coding RNA H19 in glioma via integrated bioinformatics analyses.
Xiao Y; Zhu Z; Li J; Yao J; Jiang H; Ran R; Li X; Li Z
Aging (Albany NY); 2020 Feb; 12(4):3407-3430. PubMed ID: 32081833
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
50.
Jiang Q; Wang X; Yang Q; Zhang H; Wang X
DNA Cell Biol; 2021 Nov; 40(11):1381-1395. PubMed ID: 34735293
[TBL] [Abstract][Full Text] [Related]
51. Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.
Zeng Y; Cai Y; Chai P; Mao Y; Chen Y; Wang L; Zeng K; Zhan Z; Xie Y; Li C; Zhan H; Zhao L; Chen X; Zhu X; Liu Y; Chen M; Song Y; Zhou A
Front Immunol; 2022; 13():961933. PubMed ID: 35990696
[TBL] [Abstract][Full Text] [Related]
52. Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas.
He G; Chen Z; Zhuo S; Tang J; Hao W; Yang K; Yang C
Hum Cell; 2022 Nov; 35(6):1976-1992. PubMed ID: 36129672
[TBL] [Abstract][Full Text] [Related]
53. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma.
Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB
Front Immunol; 2020; 11():606164. PubMed ID: 33408717
[TBL] [Abstract][Full Text] [Related]
54. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
55. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Ye L; Tong S; Wang Y; Wang Y; Ma W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320
[TBL] [Abstract][Full Text] [Related]
56. Integrative analysis regarding the correlation between GAS2 family genes and human glioma prognosis.
Zhao C; Zhang N; Cui X; Zhang X; Ren Y; Su C; He J; Zhang W; Sun X; Yang J; Gao X
Cancer Med; 2021 Apr; 10(8):2826-2839. PubMed ID: 33713047
[TBL] [Abstract][Full Text] [Related]
57. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
Su X; Li H; Chen S; Qin C
Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
[TBL] [Abstract][Full Text] [Related]
58. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
59. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
Wu S; Miao K; Wang L; Ma Y; Wu X
Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
[TBL] [Abstract][Full Text] [Related]
60. EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study.
Hao Z; Guo D
BMC Cancer; 2019 Dec; 19(1):1184. PubMed ID: 31801484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
